120 related articles for article (PubMed ID: 38546663)
1. Physical Activity Using a Wearable Device as an Alternative to Performance Status in Patients With Advanced Lung Cancer.
Ito K; Suzuki Y; Sakaguchi T; Fujiwara K; Nishii Y; Yasui H; Taguchi O; Hataji O
JAMA Oncol; 2024 May; 10(5):648-651. PubMed ID: 38546663
[TBL] [Abstract][Full Text] [Related]
2. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
3. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of Wearable Physical Activity Monitors in Patients With Cancer.
Gupta A; Stewart T; Bhulani N; Dong Y; Rahimi Z; Crane K; Rethorst C; Beg MS
JCO Clin Cancer Inform; 2018 Dec; 2():1-10. PubMed ID: 30652571
[TBL] [Abstract][Full Text] [Related]
6. Actigraphy as an assessment of performance status in patients with advanced lung cancer.
Fujisawa D; Temel JS; Greer JA; El-Jawahri A; Traeger L; Jacobs JM; Cutrono S; Pirl WF
Palliat Support Care; 2019 Oct; 17(5):574-578. PubMed ID: 30739635
[TBL] [Abstract][Full Text] [Related]
7. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.
Buccheri G; Ferrigno D; Tamburini M
Eur J Cancer; 1996 Jun; 32A(7):1135-41. PubMed ID: 8758243
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia.
Ruan GT; Xie HL; Yuan KT; Lin SQ; Zhang HY; Liu CA; Shi JY; Ge YZ; Song MM; Hu CL; Zhang XW; Liu XY; Yang M; Wang KH; Zheng X; Chen Y; Hu W; Cong MH; Zhu LC; Deng L; Shi HP
J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2813-2823. PubMed ID: 37902006
[TBL] [Abstract][Full Text] [Related]
10. Association of systemic inflammation and low performance status with reduced survival outcome in older adults with cancer.
Ruan GT; Xie HL; Zhang HY; Zhang Q; Deng L; Wang ZW; Zhang X; Ge YZ; Hu CL; Tang M; Song MM; Zhang XW; Liu T; Li XR; Zhang KP; Yang M; Gong YZ; Chen YB; Yu KY; Cong MH; Pan L; Tang WZ; Wang KH; Shi HP
Clin Nutr; 2022 Oct; 41(10):2284-2294. PubMed ID: 36096062
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: Implications for a clinically important framework in the assessment and treatment of advanced cancer.
Dolan RD; Daly L; Sim WMJ; Fallon M; Ryan A; McMillan DC; Laird BJ
Clin Nutr; 2020 Sep; 39(9):2889-2895. PubMed ID: 31926762
[TBL] [Abstract][Full Text] [Related]
12. "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer.
Simmons C; McMillan DC; Tuck S; Graham C; McKeown A; Bennett M; O'Neill C; Wilcock A; Usborne C; Fearon KC; Fallon M; Laird BJ;
Oncologist; 2019 Sep; 24(9):e960-e967. PubMed ID: 30975922
[TBL] [Abstract][Full Text] [Related]
13. Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?
Baldotto CS; Cronemberger EH; de Biasi P; Zamboni M; Sousa A; Zukin M; Small IA; Ferreira CG
Support Care Cancer; 2012 Nov; 20(11):2721-7. PubMed ID: 22322592
[TBL] [Abstract][Full Text] [Related]
14. Patients over 65 years are assigned lower ECOG PS scores than younger patients, although objectively measured physical activity is no different.
Broderick JM; Hussey J; Kennedy MJ; O' Donnell DM
J Geriatr Oncol; 2014 Jan; 5(1):49-56. PubMed ID: 24484718
[TBL] [Abstract][Full Text] [Related]
15. The value of physical performance measurements alongside assessment of sarcopenia in predicting receipt and completion of planned treatment in non-small cell lung cancer: an observational exploratory study.
Collins JT; Noble S; Chester J; Davies HE; Evans WD; Farewell D; Lester JF; Parry D; Pettit R; Byrne A
Support Care Cancer; 2018 Jan; 26(1):119-127. PubMed ID: 28721555
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
[TBL] [Abstract][Full Text] [Related]
18. The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study.
Takahashi M; Takahashi M; Komine K; Yamada H; Kasahara Y; Chikamatsu S; Okita A; Ito S; Ouchi K; Okada Y; Imai H; Saijo K; Shirota H; Takahashi S; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(6):e0179694. PubMed ID: 28640844
[TBL] [Abstract][Full Text] [Related]
19. An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer.
Dolan RD; Laird BJA; Klepstad P; Kaasa S; Horgan PG; Paulsen Ø; McMillan DC
Medicine (Baltimore); 2019 Sep; 98(37):e17019. PubMed ID: 31517821
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health record study.
Sadetsky N; Chuo CY; Davidoff AJ
Pharmacoepidemiol Drug Saf; 2021 Sep; 30(9):1233-1241. PubMed ID: 34145696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
